Dexamethasone implants improve visual and anatomical outcomes better than brolucizumab in patients with both DME and hyperreflective intraretinal dots.
AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...